MSMaor Sauler

Maor Sauler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maor Sauler has a total of 481 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The ferroptosis inhibitor NUPR1 coordinates the mitochondrial response to oxidative stress and cell metabolism during COPD pathogenesis in the lung

    by Jessica Nouws, Saul S. Siller, Tao Yang, So-Jin Kim, Sang-Hun Kim, Patricia Santofimia-Castaño, Juan L. Iovanna, Erica L. Herzog, John E. McDonough, Maor Sauler

    COPD is a devastating disease characterized by chronic lung injury and oxidative stress. We provide evidence that NUPR1, an inhibitor of the iron-dependent cell death program ferroptosis, is important for regulating oxidative stress, mitochondrial function, and cell metabolism in AT2 cells of the lung. We further show that loss of NUPR1 in mice contributes to increased oxidative damage and emphysematous changes of the lung, suggesting a critical role of NUPR1 in COPD pathogenesis.


  • Open Access

    Preclinical models of COPD: a state of the art review

    by Francesca Polverino, Kambez H. Benam, Suzanne M. Cloonan, Jeffrey L. Curtis, Amit Gaggar, Farrah Kheradmand, Mareike Lehmann, Enid Neptune, S. Vamsee Raju, Joselyn Rojas-Quintero, et al.

    COPD is a progressive and heterogeneous condition characterised by varying combinations of emphysema, small airway disease, chronic bronchitis and exacerbations. Although multiple symptomatic therapies exist, no disease-modifying treatments are available. This gap highlights the need for improved preclinical models with greater translational relevance. Large human cohorts and single-cell/multi-omics studies have informed the development of current COPD models. We provide a state of the art review of the major experimental platforms: in vivo (small and large animals, genetic and injury models, environmental exposures), ex vivo (precision-cut lung slices, organoids, co-cultures, lung-on-a-chip systems) and in silico (aerosol dispersion and computational tools). While each approach has yielded important mechanistic insights, none fully captures the complexity of COPD progression, comorbidities, gene–environment interactions or heterogeneous clinical endotypes. Future progress will depend on the development of more integrated, human-relevant modelling systems, alongside advanced exposure platforms and artificial intelligence-driven multi-omics integration to identify biologically meaningful endotypes and speed the creation of phenotype-specific therapies. We propose a phenotype-driven, cross-platform framework in which hypotheses emerging from human clinical and omics data are validated in in vitro and ex vivo systems, evaluated in phenotype-specific in vivo models, and ultimately confirmed through clinical studies.


  • Open Access

    New approaches to uncover COPD pathobiology and develop therapies

    by Yohannes Tesfaigzi, Ali Önder Yildirim, Francesca Polverino, Thomas M. Conlon, Venkataramana Sidhaye, Maor Sauler, S. Vamsee Raju, Renata Z. Jurkowska, Divay Chandra, Michael H. Cho, et al.

    Chronic obstructive pulmonary disease (COPD) was the third leading cause of global mortality in 2011 but receives limited attention and research funding. This Review describes the current knowledge on COPD risk factors, including genetic and epigenetic determinants and their interactions with the microbiome and environmental exposures. Preclinical models are being refined and single-cell transcriptomic, metabolomic, and proteomic technologies are being implemented to investigate the molecular mechanisms of disease progression. Patient cohorts to define biomarkers of early disease and the latest approaches to diagnose pre-COPD are essential to accelerate the development of novel and effective therapeutic interventions and translate new findings into clinical trials. This Review is a summary of topics covered by a symposium organized by the COPD-iNET consortium, an international network of researchers who have established a platform that facilitates collaboration of this multidisciplinary group of preclinical, translational, and clinical researchers.


  • Top Cited Papers
    Open Access

    Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease

    by Yuening Zhang, Huanhuan Wei, Jessica Nouws, Wenhao Jiang, Reginald M. Brewster, Jenny P. Nguyen, SiRu Liang, Samuel M. Pass, Weiwei Wang, Florine Collin, et al.

    Chronic obstructive pulmonary disease (COPD) is clinically and molecularly heterogeneous. To investigate COPD heterogeneity, we profiled lung tissue by single-nucleus RNA sequencing from 141 study participants (1,516,727 nuclei) and identified shifts in cell composition and emergent cell states that correlated with lung function, emphysema and composite symptom scores. Epithelial regenerative states peaked in early COPD and declined thereafter, whereas inflamed nonimmune cells and profibrotic/remodeling states, together with select immune populations, expanded with disease progression. Clustering study participants by the proportion of pathologic cells coupled with spatial transcriptomics identified distinct patterns of cellular co-occurrence within spatially localized niches. Proteomic analyses identified plasma biomarkers of cell states and their impact on the extracellular matrix. Mediation and cell communication analyses revealed cell-autonomous and intercellular communication networks associated with disease. These data define the cellular landscape of COPD heterogeneity, revealing molecular drivers and biomarkers that could inform therapeutic strategies.


  • Open Access

    Multi-omics to study chronic respiratory diseases and viral infections

    by Sobia Idrees, Hao Chen, Tayyaba Sadaf, Saima Firdous Rehman, Matt D. Johansen, Keshav Raj Paudel, Gang Liu, Yuting Wang, Malte D. Luecken, Elinor Hortle, et al.

    Despite recent advances, the underlying mechanisms of the development and progression of many chronic respiratory diseases remain to be elucidated. Factors such as heterogeneity and complexity of human diseases and difficulty interpreting large datasets hinder research into chronic respiratory diseases. Omics assesses the changes in specific biological entities, such as mRNA expression, epigenetics/epigenomics, genomics, proteomics, metagenomics and metabolomics, and provides valuable insights into the roles of these processes in chronic respiratory diseases. High-throughput omics at bulk, single-cell and spatial levels empower the exploration of disease-related changes through untargeted data-driven statistical methods. Multi-omics is the exploration and integration of multiple biological processes, which compared to a single-omics, can provide a substantially greater and more holistic overview of the pathogenic mechanisms that underpin complex diseases. Multi-omics analysis can comprehensively characterise the mechanisms that drive chronic respiratory diseases, capturing unique biological signatures and cellular interactions at different omics levels. Use of these methods has begun to identify key factors and biomarkers in chronic respiratory diseases. Here, we review current omics approaches and highlight recent advances in respiratory research achieved using multi-omics and integrative methods. Our review provides a valuable resource for researchers and clinicians in this area.


    • 14 January 2026
      • Vol. 35  (179)
    Open Access

    Multi-omics to study chronic respiratory diseases and viral infections.

    by Sobia Idrees, Hao Chen, Tayyaba Sadaf, Saima Firdous Rehman, Matt D Johansen, Keshav Raj Paudel, Gang Liu, Yuting Wang, Malte D Luecken, Elinor Hortle, et al.

    Despite recent advances, the underlying mechanisms of the development and progression of many chronic respiratory diseases remain to be elucidated. Factors such as heterogeneity and complexity of human diseases and difficulty interpreting large datasets hinder research into chronic respiratory diseases. Omics assesses the changes in specific biological entities, such as mRNA expression, epigenetics/epigenomics, genomics, proteomics, metagenomics and metabolomics, and provides valuable insights into the roles of these processes in chronic respiratory diseases. High-throughput omics at bulk, single-cell and spatial levels empower the exploration of disease-related changes through untargeted data-driven statistical methods. Multi-omics is the exploration and integration of multiple biological processes, which compared to a single-omics, can provide a substantially greater and more holistic overview of the pathogenic mechanisms that underpin complex diseases. Multi-omics analysis can comprehensively characterise the mechanisms that drive chronic respiratory diseases, capturing unique biological signatures and cellular interactions at different omics levels. Use of these methods has begun to identify key factors and biomarkers in chronic respiratory diseases. Here, we review current omics approaches and highlight recent advances in respiratory research achieved using multi-omics and integrative methods. Our review provides a valuable resource for researchers and clinicians in this area.


  • Open Access

    Integrative single-cell RNA and ATAC sequencing reveals the impact of chronic cigarette smoking on lung epithelial responses to influenza and hyperoxia

    by Pei-Chun Cha, Zhenyang Zou, Jessica Nouws, Reginald M. Brewster, Charles S. Dela Cruz, Lokesh Sharma, Xiting Yan, Maor Sauler

    Background: Cigarette smoke (CS) increases susceptibility to acute lung injury, yet how CS reshapes epithelial responses to subsequent insults remains unclear, and the extent to which aberrant epithelial responses are linked to epigenetic changes in vivo is uncertain. Methods: In this pilot, proof-of-principle study, we performed paired single-cell RNA-seq and ATAC-seq after chronic CS exposure followed by influenza or hyperoxia, generating joint expression–accessibility maps across epithelial subsets and inferring candidate transcriptional regulators. Results: Influenza and hyperoxia elicited distinct epithelial programs. Prior CS exposure amplified epigenetically regulated inflammatory signaling (cytokine/chemokine modules coupled to ERK/MAPK and PI3K) and suppressed epigenetically regulated reparative and differentiation pathways (γ-secretase/NOTCH). Transcription factor motif enrichment implicated ETS family factors and REL as candidate regulators of the CS-augmented responses in AT2 and ciliated cells. Conclusions: Paired single-cell RNA/ATAC profiling captures injury-conditioned epithelial programs and their epigenetic context after chronic CS exposure, demonstrating feasibility and providing a framework to prioritize targets of exposure-related aberrant responses.


  • Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling

    by Sang-Hun Kim, Jessica Nouws, Jannik Ruwisch, Gavitt A. Woodard, Joseph Cooley, Johad Khoury, Huanxing Sun, Edward Doherty, Marta Piecychna, Edward P. Manning, et al.

    Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 ( Cul3 ) deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of Mif or Mif-2 attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of Cd74 , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ( Cx3cr1 )–expressing and platelet factor 4 ( Pf4 )–expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor–β1 ( TGFB1 ) transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.